Member Info for BuenaVista

Hello and welcome, thanks for coming. We've invited some key opinion leaders along to explain to you how we've dosed terminally ill cancer patients up to the eyeballs with a cytotoxic poison and they've not suffered anything like the side effects we were hoping, sorry, expecting to see but, unfortunately the drug doesn't work, so you can all go home now. Thank you for coming.

I think StarBright is just being realistic - and very sensibly so. The outcome of Phase 1a can certainly be expected to be very good but it's not a 0% or 100% outcome; there are bound to be unanswered questions (not asked on the trial) and new questions coming from the trial (for example, what's the best administration regimen?)

The traders and shorters however are onto a loser however with the "This only says it's safe" line. As if it's safe to administer huge doses of doxorubicin, monitored for pharmacokinetics, but the doxorubicin has become magically inactive! Arf! Arf!

That's the basher's line today is it? It's only safe

Phase 1a has completed, data have been analysed, results known and presentation nearly finished.

Avacta absolutely certain that conclusions, with presentation and media blitz can be released shortly after New Year.

Key opinion leaders have full diaries (as do City analysts and fund managers) but Avacta has been persuasive and has lined them up for late February.

All good. What's not to like?

Fair enough. Yet another power unit export then!

Does the delivery of this power unit to ABB need to be RNS'ed, and if so when?

Well, as it would be delivery of a new technological application, I'd say it should be announced to the market by AFC but whether it is on being ready to despatch, on despatch, on arrival, on installation or on working would be up to AFC (unless pushed into making an announcement as they have been with the Power Towers!). However, this being a quiet time for the market, I wouldn't now expect need until early January.

So, could this have been the power unit exported in October?

Q.E.D.

New board members, beware of bashers spreading distrust for their own ends.

Remember:
- Bashers never bash a bad stock
- Bashers bash the stock of small companies with potential
- Bashers post many times a day
- Bashers repeatedly bring up old ('bad') news
- Bashers will distort the truth
- Bashers play on your lack of knowledge
- Bashers play on your lack of patience
- Bashers make statements they know you won't check
- Bashers play on your laziness
- The basher's purpose is to bring the share price down

The best way to protect yourself is to be prepared and don't engage with the basher!

Read https://bashershandbook.blogspot.com/

So only possible announcements would be a 4th dose escalation and/or a milestone payment, although the latter could be delayed till New Year.

Been doing some research.

"CD33 is the target of gemtuzumab ozogamicin (trade name: Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories),[11] an antibody-drug conjugate (ADC) for the treatment of patients with acute myeloid leukemia. The drug is a recombinant, humanized anti-CD33 monoclonal antibody (IgG4 ? antibody hP67.6) covalently attached to the cytotoxic antitumor antibiotic calicheamicin"
https://en.m.wikipedia.org/wiki/CD33

(Gemtuzumab ozogamicin sounded familiar. It was mentioned in the Daily Mail article last weekend about Cancer Research UK-funded drug trials.
https://www.dailymail.co.uk/health/article-11524005/amp/Cancer-Research-UK-funded-drug-trials-spare-children-lifelong-chemotherapy-effects.html )

The Avacta patent is for an Affimer covalently linked to a cytotoxic agent, this being taken into the cell more efficiently than the much larger conjugated antibody drug.

Type 'avacta' in the Search terms box to see a listing of patents Avacta has applied for, with or without Tufts College (William Bachovchin) as joint applicant. This will not include the Tufts College patents licensed in by Avacta.

https://patentscope.wipo.int/search/en/search.jsf

Patents with the same title and priority details applied for at different patent offices belong to the same family, so the number of different patents is a lot smaller than 53.

The most recent patent application to be published (10/11/2022, filed 5/5/2022, priority 7/5/2021), 'CD33 BINDING POLYPEPTIDES WITH STEFIN A PROTEIN', has no family members as yet and looks very interesting!

Thoughts on which area of Avacta's declared R&D it might relate to?

Common belief it is IG keeping below 3%

Forward into the death spiral!

You should definitely short it Tel, 100%. Do it now, before the SP plummets. I dare you.

Well said MrRiply, and a definite rec from me!

Who's Marik? ¯\_(?)_/¯

Ego. Such a giveaway!

But you said previously that recs weren't important. Now they are?

Queue (sic) speculation about AffiDX ® SARS-CoV-2 Antigen Lateral Flow Test Mk 2

Well done everyone, you've let the sealoion lead you off on a wild goose chase yet again. Such intelligence!